Organogenesis Holdings (Organogenesis Holdings) Forward Dividend Yield % : 0.00% (As of Jun. 09, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Forward Dividend Yield %?

As of today (2024-06-09), the Forward Annual Dividend Yield of Organogenesis Holdings is 0.00%.

As of today (2024-06-09), the Trailing Annual Dividend Yield of Organogenesis Holdings is 0.00%.

ORGO's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.95
* Ranked among companies with meaningful Forward Dividend Yield % only.

Organogenesis Holdings's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Organogenesis Holdings's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organogenesis Holdings's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Forward Dividend Yield % falls into.

Organogenesis Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Organogenesis Holdings (NAS:ORGO) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Organogenesis Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Organogenesis Holdings (Organogenesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

2PQ:Germany

Address

85 Dan Road, Canton, MA, USA, 02021

Website

https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Executives

Albert Erani	10 percent owner	150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz	10 percent owner
Arthur S Leibowitz	director	139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney	director, officer: President and CEO	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin	director	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo	officer: VP Health Policy & Contracting	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin	director	7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu	director	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf	director, 10 percent owner
Alan A. Ades	director, 10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021